GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (NAS:EDIT) » Definitions » ROE %

Editas Medicine (Editas Medicine) ROE % : -21.28% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Editas Medicine's annualized net income for the quarter that ended in Dec. 2023 was $-75.50 Mil. Editas Medicine's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $354.78 Mil. Therefore, Editas Medicine's annualized ROE % for the quarter that ended in Dec. 2023 was -21.28%.

The historical rank and industry rank for Editas Medicine's ROE % or its related term are showing as below:

EDIT' s ROE % Range Over the Past 10 Years
Min: -377.46   Med: -48.86   Max: -35.36
Current: -42.86

During the past 11 years, Editas Medicine's highest ROE % was -35.36%. The lowest was -377.46%. And the median was -48.86%.

EDIT's ROE % is ranked better than
50.63% of 1359 companies
in the Biotechnology industry
Industry Median: -44.08 vs EDIT: -42.86

Editas Medicine ROE % Historical Data

The historical data trend for Editas Medicine's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine ROE % Chart

Editas Medicine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -53.65 -35.36 -40.65 -48.22 -43.17

Editas Medicine Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.66 -57.85 -44.93 -47.36 -21.28

Competitive Comparison of Editas Medicine's ROE %

For the Biotechnology subindustry, Editas Medicine's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Editas Medicine's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's ROE % distribution charts can be found below:

* The bar in red indicates where Editas Medicine's ROE % falls into.



Editas Medicine ROE % Calculation

Editas Medicine's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-153.219/( (360.68+349.097)/ 2 )
=-153.219/354.8885
=-43.17 %

Editas Medicine's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-75.496/( (360.462+349.097)/ 2 )
=-75.496/354.7795
=-21.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Editas Medicine  (NAS:EDIT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-75.496/354.7795
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-75.496 / 240.196)*(240.196 / 501.9015)*(501.9015 / 354.7795)
=Net Margin %*Asset Turnover*Equity Multiplier
=-31.43 %*0.4786*1.4147
=ROA %*Equity Multiplier
=-15.04 %*1.4147
=-21.28 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-75.496/354.7795
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-75.496 / -75.496) * (-75.496 / -95.848) * (-95.848 / 240.196) * (240.196 / 501.9015) * (501.9015 / 354.7795)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.7877 * -39.9 % * 0.4786 * 1.4147
=-21.28 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Editas Medicine ROE % Related Terms

Thank you for viewing the detailed overview of Editas Medicine's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Editas Medicine (Editas Medicine) Business Description

Traded in Other Exchanges
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Executives
Bruce Eaton officer: EVP, Chief Business Officer C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Linda Burkly officer: EVP, CHIEF SCIENTIFIC OFFICER 1 MAIN STREET, CAMBRIDGE MA 02142
Baisong Mei officer: SVP, CHIEF MEDICAL OFFICER C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Gilmore Neil O'neill director, officer: CEO 215 FIRST STREET, CAMBRIDGE MA 02142
Erick Lucera officer: EVP, CHIEF FINANCIAL OFFICER 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Michelle Robertson officer: Chief Financial Officer C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elliott M. Levy director C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Mark S Shearman officer: EVP, Chief Scientific Officer C/O APPLIED GENETIC TECHNOLOGIES CORP, 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Lisa Anne Michaels officer: EVP/Chief Medical Officer C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Bernadette Connaughton director C/O VISTERRA, INC., ONE KENDALL SQUARE, #B3301, CAMBRIDGE MA 02139
James C Mullen director 940 WINTER STREET, PERKINELMER, INC LEGAL DEPARTMENT, WALTHAM MA 02451
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cynthia Collins director 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Meeta Chatterjee director C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142

Editas Medicine (Editas Medicine) Headlines

From GuruFocus

Editas Medicine Announces Pricing of Offering of Common Stock

By sperokesalga sperokesalga 06-15-2023